Skip to main content
SpringerLink
Log in

Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

This study was conducted to determine the efficacy and safety of low-dose chemotherapy with methotrexate (MTX) and vinblastine (VBL) for patients with desmoid tumors refractory to meloxicam treatment, focusing in particular on the relationship between the efficacy of this chemotherapy and catenin β-1 (CTNNB1) mutation status.

Patients and methods

Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution. Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week. The responses of all patients were evaluated, and factors that were correlated with efficacy were analyzed, including CTNNB1 mutation status.

Results

Sixty-eight patients were prospectively treated with meloxicam. MTX + VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression. A few patients showed grade 3–4 treatment-related toxicity with the administration of MTX and VBL every other week. Intriguingly, CTNNB1 status did not affect the efficacy of this treatment.

Conclusion

MTX and VBL treatment every other week is well tolerated and achieved a favorable response in patients resistant to meloxicam treatment, regardless of CTNNB1 mutation status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–b
Fig. 2

Similar content being viewed by others

References

  1. Posner MC, Shiu MH, Newsome JL et al (1989) The desmoid tumor. Arch Surg 124(2):191–196

    Article  CAS  PubMed  Google Scholar 

  2. Ballo MT, Zagars GK, Pollack A et al (1999) Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17(1):158–167

    CAS  PubMed  Google Scholar 

  3. Gronchi A, Casali PG, Mariani L et al (2003) Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 21(7):1390–1397

    Article  CAS  PubMed  Google Scholar 

  4. Huang K, Fu H, Shi YQ et al (2009) Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol 100(7):563–569

    Article  PubMed  Google Scholar 

  5. Lev D, Kotilingam D, Wei C et al (2007) Optimizing treatment of desmoid tumors. J Clin Oncol 25(13):1785–1791

    Article  PubMed  Google Scholar 

  6. Merchant NB, Lewis JJ, Woodruff JM et al (1999) Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 86(10):2045–2052

    Article  CAS  PubMed  Google Scholar 

  7. Nuyttens JJ, Rust PF, Thomas CR Jr et al (2000) Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer 88(7):1517–1523

    Article  CAS  PubMed  Google Scholar 

  8. Salas S, Dufresne A, Bui B et al (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29(26):3553–3558

    Article  PubMed  Google Scholar 

  9. Shido Y, Nishida Y, Nakashima H et al (2009) Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Traum Surg 129(7):929–933

    Article  Google Scholar 

  10. Colombo C, Miceli R, Lazar AJ et al (2013) CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 119(20):3696–3702

    Article  CAS  PubMed  Google Scholar 

  11. Lazar AJ, Tuvin D, Hajibashi S et al (2008) Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173(5):1518–1527

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. van Broekhoven DL, Verhoef C, Grunhagen DJ et al (2015) Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 22(5):1464–1470

    Article  PubMed  Google Scholar 

  13. Briand S, Barbier O, Biau D et al (2014) Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am 96(8):631–638

    Article  PubMed  Google Scholar 

  14. Gronchi A, Colombo C, Le Pechoux C et al (2014) Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25(3):578–583

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Nishida Y, Tsukushi S, Shido Y et al (2010) Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol 28(6):e107–e109

    Article  CAS  PubMed  Google Scholar 

  16. Skapek SX, Anderson JR, Hill DA et al (2013) Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 60(7):1108–1112

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. de Camargo VP, Keohan ML, D’Adamo DR et al (2010) Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 116(9):2258–2265

    PubMed Central  PubMed  Google Scholar 

  18. Gega M, Yanagi H, Yoshikawa R et al (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24(1):102–105

    Article  CAS  PubMed  Google Scholar 

  19. Poon R, Smits R, Li C et al (2001) Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 20(4):451–460

    Article  CAS  PubMed  Google Scholar 

  20. Hamada S, Urakawa H, Kozawa E et al (2014) Nuclear expression of beta-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors. Tumour Biol 35(5):4561–4566

    Article  CAS  PubMed  Google Scholar 

  21. Azzarelli A, Gronchi A, Bertulli R et al (2001) Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92(5):1259–1264

    Article  CAS  PubMed  Google Scholar 

  22. Lackner H, Urban C, Kerbl R (1997) Noncytotoxic drug therapy in children with unresectable desmoid tumors. Cancer 80(2):334–340

    Article  CAS  PubMed  Google Scholar 

  23. Hamada S, Futamura N, Ikuta K et al (2014) CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. PLoS One 9(5):e96391

    Article  PubMed Central  PubMed  Google Scholar 

  24. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

    Article  CAS  PubMed  Google Scholar 

  25. Skapek SX, Ferguson WS, Granowetter L et al (2007) Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 25(5):501–506

    Article  CAS  PubMed  Google Scholar 

  26. Meazza C, Bisogno G, Gronchi A et al (2010) Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer 116(1):233–240

    CAS  PubMed  Google Scholar 

  27. Garbay D, Le Cesne A, Penel N et al (2012) Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 23(1):182–186

    Article  CAS  PubMed  Google Scholar 

  28. Domont J, Salas S, Lacroix L et al (2010) High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 102(6):1032–1036

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Chugh R, Wathen JK, Patel SR et al (2010) Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16(19):4884–4891

    Article  CAS  PubMed  Google Scholar 

  30. Heinrich MC, McArthur GA, Demetri GD et al (2006) Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24(7):1195–1203

    Article  CAS  PubMed  Google Scholar 

  31. Penel N, Le Cesne A, Bui BN et al (2011) Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 22(2):452–457

    Article  CAS  PubMed  Google Scholar 

  32. Gounder MM, Lefkowitz RA, Keohan ML et al (2011) Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 17(12):4082–4090

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Jo JC, Hong YS, Kim KP et al (2014) A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Investig New Drugs 32(2):369–376

    Article  CAS  Google Scholar 

  34. Bonvalot S, Eldweny H, Haddad V et al (2008) Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 34(4):462–468

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Ms. Eri Ishihara for her secretarial assistance with this study, and Dr. Yoshie Shimoyama for pathological diagnosis. This work was supported in part by the Ministry of Education, Culture, Sports, Science and Technology of Japan [Grant-in-Aid 262933341 for Scientific Research (B)], and the Health Labour Sciences Research Grant of Japan.

Conflict of interest

Y.A. received Honoraria from Nippon Kayaku and Pfizer. Y.A. received research funding from Nippon Kayaku. The other authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan

    Yoshihiro Nishida, Satoshi Tsukushi, Hiroshi Urakawa, Shunsuke Hamada, Eiji Kozawa, Kunihiro Ikuta & Naoki Ishiguro

  2. Department of Clinical Oncology and Chemotherapy, Nagoya University Graduate School and School of Medicine, 65-Tsurumai, Showa, Nagoya, 466-8550, Japan

    Hiroshi Urakawa & Yuichi Ando

Authors
  1. Yoshihiro Nishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Tsukushi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Urakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shunsuke Hamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eiji Kozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kunihiro Ikuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuichi Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Naoki Ishiguro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Nishida.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nishida, Y., Tsukushi, S., Urakawa, H. et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status. Int J Clin Oncol 20, 1211–1217 (2015). https://doi.org/10.1007/s10147-015-0829-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-015-0829-0

Keywords

Search

Navigation